Is Regenxbio Inc (RGNX) overvalued? · rev $114.4M
Regenxbio Inc (RGNX) is a biotechnology company listed on US.
This page asks whether Regenxbio Inc (RGNX) looks expensive on cached numbers — not a short thesis.
Latest reported RGNX revenue for 2026-06-30 was $114.4M. Net income was -$67.3M. RGNX currently screens at market cap $440.4M.
RGNX currently screens at market cap $440.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RGNX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RGNX stock page for the full model, not this heading.
Not investment advice.